Aptose Biosciences (Aptose Biosciences) FCF Margin % : 0.00% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Aptose Biosciences FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aptose Biosciences's Free Cash Flow for the three months ended in Dec. 2023 was $-9.26 Mil. Aptose Biosciences's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. Therefore, Aptose Biosciences's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

As of today, Aptose Biosciences's current FCF Yield % is -225.57%.

The historical rank and industry rank for Aptose Biosciences's FCF Margin % or its related term are showing as below:

APTO's FCF Margin % is not ranked ^*
in the Biotechnology industry.
Industry Median: -147.18
* Ranked among companies with meaningful FCF Margin % only.

Aptose Biosciences FCF Margin % Historical Data

The historical data trend for Aptose Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptose Biosciences FCF Margin % Chart

Aptose Biosciences Annual Data

Trend

May14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

Aptose Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Aptose Biosciences's FCF Margin %

For the Biotechnology subindustry, Aptose Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aptose Biosciences's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aptose Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aptose Biosciences's FCF Margin % falls into.

Aptose Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aptose Biosciences's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-44.619	/	0
	=	%

Aptose Biosciences's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-9.259	/	0
	=	%

Aptose Biosciences FCF Margin % Related Terms

Thank you for viewing the detailed overview of Aptose Biosciences's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Aptose Biosciences (Aptose Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptose Biosciences Inc (NAS:APTO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

LTI:Germany APS:Canada

Address

251 Consumers Road, Suite 1105, Toronto, ON, CAN, M2J 4R3

Website

https://www.aptose.com

Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.

Executives

Bernd R. Seizinger	director	535 BOYLSTON STREET, BOSTON MA 02116
William G. Rice	director, officer: Chair, President & CEO	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Fletcher Payne	officer: SR VP & Chief Fin. Officer	260 LITTLEFIELD AVENUE, SOUTH SAN FRANCISCO CA 94080
Philippe Ledru	officer: Chief Commercial Officer	C/O APTOSE BIOSCIENCES INC., 2511 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Denis R Burger	director	CYTODYN INC., 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Erich Platzer	director
Rafael Bejar	officer: Chief Medical Officer	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Wilson Donald R. Jr.	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Holdings, Llc	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Drw Commodities, Llc	10 percent owner	540 W. MADISON ST., SUITE 2500, CHICAGO IL 60661
Warren Whitehead	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Gregory K. Chow	officer: Senior VP & CFO	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Jotin Marango	officer: Senior VP, Chief Bus. Officer	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3
Caroline M Loewy	director	300 ELLIOTT AVE WEST, SUITE 500, SEATTLE WA 98119-4114
Mark D. Vincent	director	C/O APTOSE BIOSCIENCES INC., 251 CONSUMERS ROAD, SUITE 1105, TORONTO A6 M2J 4R3